SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats.
Ipragliflozin is a novel and selective sodium-glucose cotransporter 2 (SGLT2) inhibitor that induces sustained increases in urinary glucose excretion by inhibiting renal glucose reabsorption and thereby exerting a subsequent antihyperglycemic effect. Here, we examined the effect of ipragliflozin on body weight in high-fat diet-induced (HFD) obese rats. Treatment of ipragliflozin (10mg/kg once daily) reduced body weight despite a slight increase in food intake. Dual-energy X-ray absorptiometry and computed tomography demonstrated that the reduction in body weight was accompanied by reduced visceral and subcutaneous fat masses but not lean mass or bone mineral content. Analysis of plasma and urinary parameters suggested the possibility that ipragliflozin enhanced lipolysis and fatty acid oxidation, and indirect calorimetry showed that ipragliflozin decreased the heat production rate from glucose but increased the rate from fat and lowered the respiratory exchange ratio. In conclusion, these data demonstrate that ipragliflozin-induced urinary glucose excretion specifically reduces fat mass with steady calorie loss by promoting the use of fatty acids instead of glucose as an energy source in HFD rats. By improving hyperglycemia and promoting weight reduction, ipragliflozin may prove useful in treating type 2 diabetes in obese individuals.
Drug Discovery Research, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba Ibaraki 305-8585, Japan; Department of Cell Biology and Neuroscience, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan. Electronic address: masanori.yokono@jp.astellas.com.
Masanori
M
Yokono
Drug Discovery Research, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba Ibaraki 305-8585, Japan.
Toshiyuki
T
Takasu
Drug Discovery Research, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba Ibaraki 305-8585, Japan.
Yuka
Y
Hayashizaki
Drug Discovery Research, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba Ibaraki 305-8585, Japan.
Keisuke
K
Mitsuoka
Drug Discovery Research, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba Ibaraki 305-8585, Japan.
Rumi
R
Kihara
Drug Discovery Research, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba Ibaraki 305-8585, Japan.
Yuko
Y
Muramatsu
Drug Discovery Research, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba Ibaraki 305-8585, Japan.
Sousuke
S
Miyoshi
Drug Discovery Research, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba Ibaraki 305-8585, Japan.
Atsuo
A
Tahara
Drug Discovery Research, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba Ibaraki 305-8585, Japan.
Eiji
E
Kurosaki
Translational & Development Pharmacology-Europe, Astellas Pharma Europe B.V., Sylviusweg 62, 2333 BH Leiden, The Netherlands.
Qun
Q
Li
Product Planning and Coordination Division, Research and Development Department, Kotobuki Pharmaceutical Co., Ltd., 6351 Sakaki-machi, Hanishina-gun, Nagano 389-0697, Japan.
Hiroshi
H
Tomiyama
Drug Discovery Research, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba Ibaraki 305-8585, Japan.
Masao
M
Sasamata
Drug Discovery Research, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba Ibaraki 305-8585, Japan.
Masayuki
M
Shibasaki
Department of Cell Biology and Neuroscience, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan.
Yasuo
Y
Uchiyama
D050154:Adiposity / Q000187:drug effects*; D000818:Animals; D019440:Anti-Obesity Agents / Q000494:pharmacology*; D015415:Biomarkers / Q000097:blood / Q000652:urine; D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism; D059305:Diet, High-Fat; D004195:Disease Models, Animal; D004734:Energy Metabolism / Q000187:drug effects; D005227:Fatty Acids / Q000378:metabolism*; D005960:Glucosides / Q000494:pharmacology*; D006029:Glycosuria / Q000378:metabolism; D007004:Hypoglycemic Agents / Q000494:pharmacology; D050356:Lipid Metabolism / Q000187:drug effects*; D009765:Obesity / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism / Q000503:physiopathology; D010084:Oxidation-Reduction; D051381:Rats; D051297:Sodium-Glucose Transporter 2 / Q000378:metabolism; D000077203:Sodium-Glucose Transporter 2 Inhibitors; D013876:Thiophenes / Q000494:pharmacology*; D013997:Time Factors; D015854:Up-Regulation; D015431:Weight Loss / Q000187:drug effects
D019440:Anti-Obesity Agents; D015415:Biomarkers; D001786:Blood Glucose; D005227:Fatty Acids; D005960:Glucosides; D007004:Hypoglycemic Agents; C490300:Slc5a2 protein, rat; D051297:Sodium-Glucose Transporter 2; D000077203:Sodium-Glucose Transporter 2 Inhibitors; D013876:Thiophenes; C572941:ipragliflozin
Diabetes; High-fat diet; Ipragliflozin; Obesity; Sodium–glucose cotransporter 2; Urinary glucose excretion